ArticleBiomacromolecules2010
Multivalent protein polymer MRI contrast agents: controlling relaxivity via modulation of amino acid sequence.
Article in Biomacromolecules, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Human Transthyretin with a Tailored Gd(III) Complex as a High-Relaxivity MRI Contrast Agent.Inorganic chemistry · 2026Article
- In Vivo Evaluation of Innovative Gadolinium-Based Contrast Agents Designed for Bioimaging Applications.Polymers · 2024Article
- Large Protein Assemblies for High-Relaxivity Contrast Agents: The Case of Gadolinium-Labeled Asparaginase.Bioconjugate chemistry · 2022Article
- Cyclodextrins: promising scaffolds for MRI contrast agents.RSC advances · 2021Review
- Nanotechnology and its use in imaging and drug delivery (Review).Biomedical reports · 2021Review
- Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma.International journal of nanomedicine · 2020Article
- Gd(III)-labeled peptide nanofibers for reporting on biomaterial localization in vivo.ACS nano · 2014Article
- Mechanisms of Gadographene-Mediated Proton Spin Relaxation.The journal of physical chemistry. C, Nanomaterials and interfaces · 2013Article
- Metalloprotein-based MRI probes.FEBS letters · 2013Review
- Transferrin-coated gadolinium nanoparticles as MRI contrast agent.Molecular imaging and biology · 2013Article
- Multifunctional dendrimer-based nanoparticles for in vivo MR/CT dual-modal molecular imaging of breast cancer.International journal of nanomedicine · 2013Article
- Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?Macromolecules · 2012Article
- Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading.Nature chemistry · 2012Article
- An extracellular MRI polymeric contrast agent that degrades at physiological pH.Molecular pharmaceutics · 2012Article
- A modular system for the synthesis of multiplexed magnetic resonance probes.Journal of the American Chemical Society · 2011Article
- Protein polymer MRI contrast agents: Longitudinal analysis of biomaterials in vivo.Magnetic resonance in medicine · 2011Article
- Sol and gel states in peptide hydrogels visualized by Gd(III)-enhanced magnetic resonance imaging.Biopolymers · 2011Article
- Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Magnetic resonance imaging is a noninvasive imaging modality with high spatial and temporal resolution. Contrast agents (CAs) are frequently used to increase the contrast between tissues of interest. To increase the effectiveness of MR agents, small molecule CAs have been attached to macromolecules. We have created a family of biodegradable, macromolecular CAs based on protein polymers, allowing control over the CA properties. The protein polymers are monodisperse, random coil, and contain evenly spaced lysines that serve as reactive sites for Gd(III) chelates. The exact sequence and length of the protein can be specified, enabling controlled variation in lysine spacing and molecular weight. Relaxivity could be modulated by changing protein polymer length and lysine spacing. Relaxivities of up to approximately 14 mM(-1) s(-1) per Gd(III) and approximately 461 mM(-1) s(-1) per conjugate were observed. These CAs are biodegradable by incubation with plasmin, such that they can be easily excreted after use. They do not reduce cell viability, a prerequisite for future in vivo studies. The protein polymer CAs can be customized for different clinical diagnostic applications, including biomaterial tracking, as a balanced agent with high relaxivity and appropriate molar mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.